Immunity: Chinese scientists detect SARS-CoV-2-specific antibody response and T-cell response in COVID-19 rehab

2020 May 18 News /BioValleyBIOON / --- A new study shows that most patients will have recently recovered from COVID-19 in just over discharged virus-specific antibodies and T cells, but a different immune response in different patientsAlthough the new study of 14 patients showed a wide range of immune responses, but one of the six patients after discharge to assess results at two weeks showed that antibodies to maintain at least so longThe other results of the new study indicate which parts of the SARS-CoV-2 virus most effectively trigger the immune response, and should therefore be developed as potential vaccine targetsThe results of recent research published in the journal Immunity, the paper titled "DetectionofSARS-CoV-2-SpecificHumoralandCellularImmunityinCOVID-19ConvalescentIndividuals"images from Immunity, 2020, doi: 10.1016 / j.immuni.2020.04.023is not clear why a big difference in the immune response of different patientsThese authors say that this difference may be that their physical condition or microbiota related to the number of patients initially encountered the virusOther unresolved issues include whether these immune responses can prevent COVID-19 after re-exposure to SARS-CoV-2 produced, and which type of activated T cells are infected with the virusIt is also worth noting that, for laboratory tests to detect human SARS-CoV-2 antibody still need further validation, to determine its accuracy and reliabilityCo-corresponding authorpaper, China Tsinghua University School of Medicine dean Dong Chen (ChenDong) professor said, "These findings suggest, B cells and T cells are involved in immune-mediated protection against viral infection our study provides further analysis of protective immunity and understanding of the mechanism COVID-19 of the base, especially in the intensive COVID 19-casesthis is also the design of effective vaccines to prevent infection have a certain significance"
co-corresponding authorpapers, Academy of military Medical Sciences Qincheng Feng (Cheng-FengQin) professor added that, with regard to the pathogenic virus SARS-CoV-2 induced a protective immune response, relatively few people are now known to fill this knowledge gap is likely to accelerate the development of an effective vaccinethis objective in mind, the researchers compared 14 has recently become immune response to virus-free COVID-19 patients and six healthy donors In these 14 patients, 8 people just discharged from hospital and the remaining six people who carry out follow-up analysis two weeks ago has been discharged in the new study Specifically, they collected blood samples, and to assess the level of immunoglobulin M (IgM) antibody, IgM antibody is an antibody which in dealing with infection appears first, and immunoglobulin G (IgG) antibody is blood circulation the most common type of antibody compared to healthy controls, and follow-up of patients newly discharged patients exhibit higher levels of IgM and IgG antibodies, these antibodies can be wrapped with the nucleocapsid SARS-CoV-2 genomic RNA binding protein and the S protein receptor binding domain (S-RBD) binding Taken together, these findings suggest that, COVID-19 patient can produce an antibody response to SARS-CoV-2 protein, and noted that these antibodies can be maintained for at least two weeks after discharge addition, five patients with higher concentrations of antibody and immediately discharged, and these antibodies may be combined with the expression of SARS-CoV-2S protein pseudovirus Neutralizing antibodies can prevent interaction between the infectious viral particle and host cell Furthermore, in addition to a follow-up of patients with all other patients had detectable neutralizing antibodies against this fake virus Secrete interferon γ (IFNγ) compared to healthy controls, five patients newly discharged with higher concentrations of one kind --- plays a key role in the immune signaling molecules - - T cells as a response to SARS-CoV-2 nucleocapsid protein made It is these patients have a higher neutralizing antibody concentration In addition, three patients just discharged exhibit detectable IFNγ secreting the SARS-CoV-2 Main Proteinase (mainprotease) --- one kind plays a key role in viral replication protein specific --- T cells At the same time, just discharged seven patients showed detectable IFNγ secreting the SARS-CoV-2S-RBD-specific T cells In contrast, only one follow-up of patients having a higher concentration of IFNγ secreted SARS-CoV-2 nucleocapsid protein, protease, and S-RBD main specific T cells Found a potentially clinically significant that the number of positive correlation with neutralizing antibody against S-RBD of IgG antibodies, but not with IgG antibody binding nucleocapsid protein In addition, S-RBD and induce antibody response and T cell responses Co-author of the paper communications, Tsinghua University Affiliated Hospital, vice president Chen Fang Chuiyangliu (FangChen) Beijing professor said, "Our results show that, S-RBD is a SARS-CoV-2 vaccine development of promising targets However, we found that needs to be confirmed in a larger cohort of patients COVID-19 "
(Biovalley Bioon.com) reference: 1 LingNietal DetectionofSARS-CoV-2-specifichumoralandcellularimmunityinCOVID-19convalescentindividuals .Immunity, 2020, doi:. 10.1016 / j.immuni.2020.04.023 2.RecentlyrecoveredCOVID-19patientsproducevaryingvirus-specificantibodies
https://medicalxpress.com/news/2020-05-recovered-covid-patients-varying-virus-specific.html